Although sEH inhibition did not change HF-diet–increased plasma cholesterol level and insulin resistance, the elevated blood pressure, hepatic steatosis, and liver content of triglycerides and cholesterol were significantly attenuated with sEHI treatment (Fig. 4E). This evidence concerns the gene EPHX2 and fatty liver disease.